United Therapeutics (UTHR)
(Real Time Quote from BATS)
$355.15 USD
+2.15 (0.61%)
Updated Sep 23, 2024 03:46 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 101 - 120 ( 611 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2: Tyvaso Tailwinds from DPI and CMS Support Continued Growth
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
KOL Call Highlights: Insights into the PAH Commercial & Clinical Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso DPI on Track to Change PH-ILD and PAH Treatment Paradigm; Reit. Buy and Raising PT to $255
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Easy, BREEZE-y: FDA Approves Tyvaso DPI for PAH & PH-ILD
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pulmonary Platform Set to Expand-Tyvaso DPI Decision Anticipated This Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1: Anticipated Tyvaso DPI Approval in May; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso DPI Full Steam Ahead, Despite Minor FDA Regulatory Setback
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department